Pages that link to "Q70905436"

The following pages link to Confidence intervals for cost/effectiveness ratios (Q70905436):

Displaying 34 items.

• The probability of cost-effectiveness (Q24805121) (← links)
• Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data (Q30653245) (← links)
• A framework for cost-effectiveness analysis from clinical trial data. (Q30654009) (← links)
• An illustration of the modelling of cost and efficacy data from a clinical trial (Q30775469) (← links)
• A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data (Q30985726) (← links)
• Incremental net benefit in randomized clinical trials with quality-adjusted survival. (Q33148478) (← links)
• Using covariates to reduce uncertainty in the economic evaluation of clinical trial data (Q33208109) (← links)
• Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials (Q33603860) (← links)
• On the use of survival analysis techniques to estimate medical care costs (Q33761363) (← links)
• Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. (Q33914367) (← links)
• Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies (Q35026968) (← links)
• Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party (Q36599584) (← links)
• Sample size determination for cost-effectiveness trials (Q37944317) (← links)
• Cost-effectiveness analysis with risk aversion (Q40687246) (← links)
• Body mass index and future healthcare costs: a retrospective cohort study. (Q40711120) (← links)
• Management of nonsteroidal anti-inflammatory drug-associated lesions: a cost-effectiveness perspective (Q41757707) (← links)
• Handling uncertainty in economic evaluations of healthcare interventions (Q42763951) (← links)
• Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation (Q43912882) (← links)
• Cost-effectiveness acceptability curves revisited (Q45710710) (← links)
• Globally optimal trial design for local decision making (Q47692291) (← links)
• Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype 'a'. (Q49834339) (← links)
• Statistical cost-effectiveness analysis of two treatments based on net health benefits. (Q52065721) (← links)
• Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. (Q52082237) (← links)
• The effect of outliers on confidence interval procedures for cost-effectiveness ratios. (Q52931266) (← links)
• A bootstrap approach to medical decision analysis. (Q53589199) (← links)
• Cluster randomized trials: Another problem for cost-effectiveness ratios (Q57404775) (← links)
• Stochastic league tables: an application to diabetes interventions in the Netherlands. (Q58476514) (← links)
• Case study in the Bayesian analysis of a cost-effectiveness trial in the evaluation of health care technologies: Depression (Q61856240) (← links)
• Using decision analytic methods to assess the utility of family history tools (Q64127355) (← links)
• The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (Q73122940) (← links)
• Costs and Cost-Effectiveness in Hip and Knee Replacements:A Prospective Study (Q74265327) (← links)
• Use of confidence intervals in health economic studies (Q77088082) (← links)
• A note on confidence intervals in cost-effectiveness analysis (Q77438005) (← links)
• Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility (Q80890679) (← links)